The Effect of Pasteurized; Pasteurized and Homogenized and UHT Treated Homogenized Cow's Milk on Gastrointestinal Symptoms in Sensitive Adults

May 24, 2022 updated by: Kaisa Linderborg, University of Turku

The Effect of Pasteurized; Pasteurized and Homogenized and UHT -Treated Homogenized Cow's Milk on Gastrointestinal Symptoms in Sensitive Adults

This study aims to investigate differences in digestion rates and gastrointestinal problems caused by pasteurized; pasturized and homogenized as well as UHT-treated homogenized cow's milks in healthy adults by diary of symptoms, blood glucose and triacylglycerol levels and plasma cytokine levels.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Finland
      • Turku, Finland, 20014
        • Department of Biochemistry, University of Turku
      • Turku, Finland, 20500
        • Food Chemistry, Department of Biochemistry, University of Turku

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Homogenized and pasteurized milk causes gastrointestinal problems (self-reported) unhomogenized and unpasteurized milk does not cause gastrointestinal problems (self-reported)
  • age 18-65
  • BMI 18,5 - 30
  • hemoglobin under normal range
  • fasting plasma alanine aminotransferase ALAT < 60 U/l (normal liver function)
  • fasting plasma thyroid-stimulating hormone (TSH) 0.4 - 4.5 mU/l (normal thyroid function)
  • fasting plasma creatinine < 118 umol/l (normal kidney function)

Exclusion Criteria:

  • pace maker
  • Crohn's disease or other disease of the intestinal tract
  • intestinal operation within the last 3 months
  • difficult dysphagia
  • smoking
  • constipation
  • lactose intolerance
  • coeliac disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: pasteurized milk
milk that has undergone pasteurization treatment
Other: Dietary intervention
Experimental: homogenized pasteurized milk
Milk that has undergone homogenization and pasteurization treatment
Other: Dietary intervention
Experimental: UHT milk
Milk that has undergone homogenization and ultra high temperature treatment
Other: Dietary intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gastrointestinal symptoms (self reported)
Time Frame: day 0 - day 5
Gastrointestinal symptoms (self-reported) as measured by a questionnaire. The questionnaire is devided into seven types of gastrointestinal discomfort, and also includes a possibility to describe a gastrointestinal discomfort outside these seven given alternatives. The severity of the symptoms is self-reported on a three-step scale.
day 0 - day 5

Secondary Outcome Measures

Outcome Measure
Time Frame
Plasma triacylglycerols
Time Frame: 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min
20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min
Plasma glucose
Time Frame: 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min
20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min
Plasma insulin
Time Frame: 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min
20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Turku

Investigators

  • Principal Investigator: Kaisa M Linderborg, PhD, Department of Biochemistry, University of Turku

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2017

Primary Completion (Actual)

May 1, 2018

Study Completion (Actual)

May 1, 2018

Study Registration Dates

First Submitted

January 4, 2017

First Submitted That Met QC Criteria

January 4, 2017

First Posted (Estimate)

January 5, 2017

Study Record Updates

Last Update Posted (Actual)

May 25, 2022

Last Update Submitted That Met QC Criteria

May 24, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MILK2

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Unidentified Gastrointestinal Discomfort Following Dairy Consumption

Clinical Trials on Dietary intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe